ALK and non-small cell lung carcinoma: Various RTKs, such as epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (HGFR/c-Met), and anaplastic lymphoma kinase (ALK), have been targeted for the development of therapeutics, as these are found to be often mutated in NSCLC patients [5].